Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
sex related phenotypic differences in myotonic dystrophy types 1 and 2 a nationwide registry study from serbia
Original title: “Sex-related phenotypic differences in myotonic dystrophy types 1 and 2: a nationwide registry study from Serbia.”
3d radiomic texture analysis of quantitative muscle mri enhances the distinction between myotonic dystrophy type 1 and charcot marie tooth neuropathy type 1a a proof of concept study
Original title: “3D Radiomic Texture Analysis of Quantitative Muscle MRI Enhances the Distinction Between Myotonic Dystrophy Type 1 and Charcot-Marie-Tooth Neuropathy Type 1A: A Proof-of-Concept Study.”
genotype phenotype relationship in a cohort of 131 chinese patients with myotonic dystrophy type 1
Original title: “Genotype-phenotype relationship in a cohort of 131 Chinese patients with myotonic dystrophy type 1.”
Analysts homed in on Duchenne muscular dystrophy and myotonic dystrophy type 1 assets during first quarter earnings as major players like REGENXBIO and Novartis as well as Dyne, Wave, Solid and Sarepta near the regulatory finish line.
Original title: “REGENXBIO, Novartis, Dyne near FDA submissions in muscular dystrophies”
evaluating the performance of chatgpt in responding to myotonic dystrophy type 1 patient inquiries a specialist physician based study
Original title: “Evaluating the performance of ChatGPT in responding to myotonic dystrophy type 1 patient inquiries: a specialist physician-based study.”
PepGen’s lead candidate for myotonic dystrophy type 1 barely beat the placebo in a Phase 2 trial in terms of fixing incorrect gene splicing, but the biotech attributed the poor result to an outlier.
Original title: “PepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting Disease”
delpacibart etedesiran improves the molecular pathology of myotonic dystrophy type 1 in the phase 1 2 marina study
Original title: “Delpacibart Etedesiran Improves the Molecular Pathology of Myotonic Dystrophy Type 1 in the Phase 1/2 MARINA® Study.”
antibody oligonucleotide conjugate for myotonic dystrophy type 1
Original title: “An Antibody-Oligonucleotide Conjugate for Myotonic Dystrophy Type 1.”
minute by minute gait variations during the 6 minute walk test in subjects with myotonic dystrophy type 1
Original title: “Minute-by minute gait variations during the 6-Minute walk test in subjects with myotonic dystrophy type 1.”